Genomics / Transcriptomics

Firalis provides a complete solution for all your genomic/transcriptomic discovery & profiling needs. We can provide you with next generation sequencing and qRT-PCR profiling services for the most complete genome and transcriptome analysis of your samples.

The HTG EdgeSeq system, available at Firalis (referent lab for Europe), is a novel target capture and library prep chemistry technology which enables fast and easy profiling of microRNA (miRNA) and messenger RNA (mRNA). The HTG EdgeSeq system uses an extraction-free chemistry that significantly reduces sample input requirements and variability associated to the extraction step. In just 3 days, our scientists can go from raw samples to data for up to 96 samples.

Key advantages of the HTG EdgeSeq:

  • Extraction-free chemistry
  • Minimal sample input
    • 15μL for serum/plasma
    • 10µg of frozen tissues
    • 1 x5 µm tissue section for FFPE slides or fresh tissues
    • 32µL of whole blood in PAXgene tubes
    • 1,5 to 10 ng purified RNA
  • Very high reproducibility (*R²> 0.98)
  • High sensitivity of the next generation sequencing

 

HTG-NGS-Worflow V2

 

  • miRNA Whole Transcriptome Assay (WTA): measures the expression of 2083 microRNAs (miRNAs) described in the miRBase v20 database using next-generation sequencing detection technology
  • Oncology Biomarker Panel: Targets 2560 mRNAs cancer-related genes through 24 groups and pathways. The panel includes a broad range of biomarkers relevant for breast, lung, melanoma, colon, and prostate cancer.
  • Immuno-Oncology Assay: a unique assay targeting 549 genes implicated in the host immune response to tumors for many applications (immune response profiling in tumors, drug targets assessment, prognostic drug signatures development, FACS cells profiling, etc.).
  • DLBCL Cell of Origin Assay: provides a subtype classifier that identifies Activated B-Cell like (ABC), Germinal Center B-cell like (GCB) or “unclassified” cells.
  • Lymphoma Panel: measures the expression of 93 genes frequently assessed in lymphomas, including 22 common non-Hodgkins lymphoma (NHL) B-cell lymphoma markers.

 

The Illumina NextSeq 500 is the desktop NGS system optimized for speed and long reads. The Flow Cells produce up to 400 million reads with read lengths between up to 150 bp by either single (SR) or paired end (PE) reads to generate up to 120 Gb of data per day. Multiple samples can be multiplexed onto a single cartridge to more efficiently distribute the reads.

Illumina NextSeq 500

Due to its deep sequencing capabilities, the NextSeq 500 instrument enables a wide variety of applications:

  • Whole genome sequencing
  • Exome analysis
  • Transcriptome analysis
  • Targeted sequencing
  • Amplicon sequencing

 

Illumina NextSeq 500 Applications

This unique technology coupled to our HTG EdgeSeq system successfully performs identification of new transcripts, such as miRNA and lncRNA or characterization of rare variants, as a wide number of reads can be done in order to confirm the discovery. Firalis can be your partner of choice by providing you its expertise in order to enhance your research.

Key strengths of our NextSeq 500 platform:

  • Adaptive to your project with Mid Output Flowcell (up to 130 million single reads or 260 million PE reads) or High Output Flowcell (up to 400 million single reads or 800 million PE reads)
  • Read lengths up to 2×150 bp resulting in up to 120 data per run
  • High multiplexing capabilities with up to 96 samples in a single run
  • RNA-Sequencing of mRNA and lncRNA (via polyA selection)
  • Whole Transcriptome Assay: mRNA, lncRNA and nuclear RNA (via rRNA depletion)
  • Sequencing of small RNA/miRNA

 

Our NextSeq 500 system is associated with a BaseSpace on-site server for a secure, safe and local environment avoiding data transfer to the cloud. All data are kept on-site which enables us to store, analyze, and share sequencing data. The data analysis are performed with different Basespace apps and Partek Genomic Suite.

Illumina BaseSpace

 

The Biomark™ HD is the industry-leading high-throughput real-time PCR instrument developed by Fluidigm. The Biomark’s Integrated Fluidic Circuit (IFC) technology prepares and performs up to 9,216 qPCR reaction per plate in nanoliter volumes, a savings time and money over more conventional qPCR assay techniques.

The Biomark™ HD is ideal for a targeted analysis approach, compared to microarray or next generation sequencing. Also, for validation studies, multiple samples can be screened against 96 different targets. It design experiments to match your needs across the widest range of genomic applications and detect unique molecular signatures in individual cells and rare cell populations.

Biomarker HD

Biomark™ HD

Key applications include:

  • Gene expression (real-time PCR): High-throughput gene expression analysis can be conducted on RNA miRNA and lncRNA using either Taqman, Sybr Green or Eva Green assays.
  • Genotyping with the detection of single nucleotide polymorphism (SNP) (end-point PCR): High-throughput genotyping with Taqman assays. A powerful tool for understanding disease disposition and drug metabolism with low sample concentrations (only ≥60 ng/μL of human genome size equivalent is required)

The Biomark™ HD supports a broad range of projects through the use of different plate formats that are compatible with Taqman™, SNPtype™ and DELTAgene™ assays. Our HX controller is designed to prime and load Dynamic Array IFCs which allows high-throughput gene expression analysis of 12 or 96 target genes in 12/96 samples or testing of 12/96 SNPs in 12/96 patient samples .

The integrated fluidics circuit (IFC) controllers push samples and reagents through channels until full; then coordinated releasing and closing of fluidic valves allows mixing of samples and reagents into individual compartments within the silicon chip saving thousands of pipetting steps. Each compartment contains only a few nanoliters total volume of the qPCR reaction. The chips are then loaded onto the Biomark™ HD System. The Flex Six and 96.96 Dynamic Array chip can simultaneously analyze up to 144 or 9,216 reactions, respectively.

Flex_six_96.96

 

Open IFC controller HX with 96.96 Dynamic array

IFC_Controller

 

The key benefits of the system include:

  • high-throughput (up to 40,000 qPCR reactions per day possible)
  • low reagent consumption (nanoliter reaction chambers)
  • reproducible results from populations of cells
  • high flexibility with different Dynamic Array

 

Workflow: Fast and Easy

 Work_flow_fast_easy

 

 

 

 

 

 

A time and cost effective solution

Classical PCR Biomark™ HD
384 samples x 96 genes 384 samples x 96 genes
184 mL master mix 960 µL master mix
18 mL primer-probes 960 µL primer-probes
96 384 well-plates 4 96.96 plates
Turnaround time: 32 days Turnaround time: 1 day

 

The qPCR platform ABI7900HT is set up on a 384 well plate format for high throughput target detection by real time PCR. Also available, the Taqman low density array (TLDA) module allows custom assay design and assay configuration flexibility. From up to 380 assays on a single sample to 32 assays on 8 samples per plate, choose the assay that is right for you to validate your signature or profile your samples

Our team of experts helps you for a successful experiment design in order to discover new variant markers and to assess gene expression and regulation, speeding up your clinical development. The NGS platform at Firalis enables also to monitor your promising therapies and to analyze pathology profiling e.g cancers, inflammatory disorders and neurodegenerative diseases.

Whether seeking a cutting edge technology, expert hand to your research or taking your business to the next level, don’t hesitate to contact us at sales@firalis.com to get further details about Firalis Biomarker Services and to discuss your projects.